These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 24794746

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43. Elucidation of the contribution of active site and exosite interactions to affinity and specificity of peptidylic serine protease inhibitors using non-natural arginine analogs.
    Hosseini M, Jiang L, Sørensen HP, Jensen JK, Christensen A, Fogh S, Yuan C, Andersen LM, Huang M, Andreasen PA, Jensen KJ.
    Mol Pharmacol; 2011 Oct; 80(4):585-97. PubMed ID: 21719463
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Crystal structure of an elastase-specific inhibitor elafin complexed with porcine pancreatic elastase determined at 1.9 A resolution.
    Tsunemi M, Matsuura Y, Sakakibara S, Katsube Y.
    Biochemistry; 1996 Sep 10; 35(36):11570-6. PubMed ID: 8794736
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Incorporation of neutral C-terminal residues in 3-amidinophenylalanine-derived matriptase inhibitors.
    Schweinitz A, Dönnecke D, Ludwig A, Steinmetzer P, Schulze A, Kotthaus J, Wein S, Clement B, Steinmetzer T.
    Bioorg Med Chem Lett; 2009 Apr 01; 19(7):1960-5. PubMed ID: 19250826
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Engineering of a macromolecular scaffold to develop specific protease inhibitors.
    Stoop AA, Craik CS.
    Nat Biotechnol; 2003 Sep 01; 21(9):1063-8. PubMed ID: 12923547
    [Abstract] [Full Text] [Related]

  • 50. Phosphono Bisbenzguanidines as Irreversible Dipeptidomimetic Inhibitors and Activity-Based Probes of Matriptase-2.
    Häußler D, Mangold M, Furtmann N, Braune A, Blaut M, Bajorath J, Stirnberg M, Gütschow M.
    Chemistry; 2016 Jun 13; 22(25):8525-35. PubMed ID: 27214780
    [Abstract] [Full Text] [Related]

  • 51. Modification of the N-terminal sulfonyl residue in 3-amidinophenylalanine-based matriptase inhibitors.
    Steinmetzer T, Dönnecke D, Korsonewski M, Neuwirth C, Steinmetzer P, Schulze A, Saupe SM, Schweinitz A.
    Bioorg Med Chem Lett; 2009 Jan 01; 19(1):67-73. PubMed ID: 19036586
    [Abstract] [Full Text] [Related]

  • 52. A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1.
    Saleem M, Adhami VM, Zhong W, Longley BJ, Lin CY, Dickson RB, Reagan-Shaw S, Jarrard DF, Mukhtar H.
    Cancer Epidemiol Biomarkers Prev; 2006 Feb 01; 15(2):217-27. PubMed ID: 16492908
    [Abstract] [Full Text] [Related]

  • 53. Selection of High-Affinity Peptidic Serine Protease Inhibitors with Increased Binding Entropy from a Back-Flip Library of Peptide-Protease Fusions.
    Sørensen HP, Xu P, Jiang L, Kromann-Hansen T, Jensen KJ, Huang M, Andreasen PA.
    J Mol Biol; 2015 Sep 25; 427(19):3110-22. PubMed ID: 26281711
    [Abstract] [Full Text] [Related]

  • 54. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
    McGowen R, Biliran H, Sager R, Sheng S.
    Cancer Res; 2000 Sep 01; 60(17):4771-8. PubMed ID: 10987285
    [Abstract] [Full Text] [Related]

  • 55. Synthesis and evaluation of the sunflower derived trypsin inhibitor as a potent inhibitor of the type II transmembrane serine protease, matriptase.
    Long YQ, Lee SL, Lin CY, Enyedy IJ, Wang S, Li P, Dickson RB, Roller PP.
    Bioorg Med Chem Lett; 2001 Sep 17; 11(18):2515-9. PubMed ID: 11549459
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Synthesis of novel thrombin inhibitors. Use of ring-closing metathesis reactions for synthesis of P2 cyclopentene- and cyclohexenedicarboxylic acid derivatives.
    Thorstensson F, Kvarnström I, Musil D, Nilsson I, Samuelsson B.
    J Med Chem; 2003 Mar 27; 46(7):1165-79. PubMed ID: 12646027
    [Abstract] [Full Text] [Related]

  • 58. QSAR and Docking Studies on Piperidyl-cyclohexylurea Derivatives for Prediction of Selective and Potent Inhibitor of Matriptase.
    Mirza AZ, Shamshad H.
    Curr Comput Aided Drug Des; 2019 Mar 27; 15(2):167-181. PubMed ID: 29769007
    [Abstract] [Full Text] [Related]

  • 59. Improving the selectivity of 3-amidinophenylalanine-derived matriptase inhibitors.
    Pilgram O, Keils A, Benary GE, Müller J, Merkl S, Ngaha S, Huber S, Chevillard F, Harbig A, Magdolen V, Heine A, Böttcher-Friebertshäuser E, Steinmetzer T.
    Eur J Med Chem; 2022 Aug 05; 238():114437. PubMed ID: 35635944
    [Abstract] [Full Text] [Related]

  • 60. Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease.
    Lee SL, Dickson RB, Lin CY.
    J Biol Chem; 2000 Nov 24; 275(47):36720-5. PubMed ID: 10962009
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.